When Novartis made clear its intention to acquire Chiron in 2005, a potentially important therapy for lung transplant patients was squeezed out by a numbers game. The drug candidate was an inhaled version of the immunosuppressant cyclosporine, and in a trial it had dramatically improved survival in lung transplant patients. Now, APT Pharmaceuticals takes over where Novartis left off, and it's preparing for a Phase III trial of the lung transplant drug.
700 Airport Boulevard
Suite 350
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.
Plus deals involving TandemAI/Perpetual Medicines, Biocytogen/BeOne, Chugai/Gero, CStone/Istituto Gentili, Alembic/Utility, Brii/Joincare, HanchorBio/Henlius, Rakuten/Cyntec and more.
Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.
IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.